0000950170-23-063926.txt : 20231114 0000950170-23-063926.hdr.sgml : 20231114 20231114192253 ACCESSION NUMBER: 0000950170-23-063926 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20231110 FILED AS OF DATE: 20231114 DATE AS OF CHANGE: 20231114 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: JENSEN MICHAEL VANGSTED CENTRAL INDEX KEY: 0001914184 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-37566 FILM NUMBER: 231408621 MAIL ADDRESS: STREET 1: 301 BINNEY STREET, SUITE 402 CITY: CAMBRIDGE STATE: MA ZIP: 02142 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: SYNLOGIC, INC. CENTRAL INDEX KEY: 0001527599 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 261824804 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 301 BINNEY STREET STREET 2: SUITE 402 CITY: CAMBRIDGE STATE: MA ZIP: 02142 BUSINESS PHONE: 617-401-9975 MAIL ADDRESS: STREET 1: 301 BINNEY STREET STREET 2: SUITE 402 CITY: CAMBRIDGE STATE: MA ZIP: 02142 FORMER COMPANY: FORMER CONFORMED NAME: Mirna Therapeutics, Inc. DATE OF NAME CHANGE: 20110809 4 1 ownership.xml 4 X0508 4 2023-11-10 0001527599 SYNLOGIC, INC. SYBX 0001914184 JENSEN MICHAEL VANGSTED C/O SYNLOGIC, INC. 301 BINNEY STREET, SUITE 402 CAMBRIDGE MA 02142 true Chief Financial Officer false Stock Option (right to buy) 33.45 2023-11-10 4 D false 15332 D 2032-03-03 Common Stock 15332 0 D Stock Option (right to buy) 9.30 2023-11-10 4 D false 13332 D 2033-03-16 Common Stock 13332 0 D Stock Option (right to buy) 9.30 2023-11-10 4 D false 6666 D 2033-03-16 Common Stock 6666 0 D Stock Option (right to buy) 1.85 2023-11-10 4 A false 15332 A 2032-03-03 Common Stock 15332 15332 D Stock Option (right to buy) 1.85 2023-11-10 4 A false 13332 A 2033-03-16 Common Stock 13332 13332 D Stock Option (right to buy) 1.85 2023-11-10 4 A false 6666 A 2033-03-16 Common Stock 6666 6666 D In accordance with the terms of the Synlogic, Inc. 2015 Equity Incentive Award Plan and the Company's 2017 Stock Incentive Plan (together the "Plans"), the Board of Directors of Synlogic, Inc. approved a stock option repricing pursuant to which option awards granted under the Plans were amended to reduce the exercise price to $1.85 per share, the closing stock price of the Company's Common Stock on November 10, 2023. Except for the modified exercise price, all other terms and conditions of each of the option awards will continue as set forth in the Plan and the applicable award agreements. These stock options vested 25% on the first anniversary of the March 3, 2022 grant date, and vest in 36 substantially-equal monthly installments thereafter, subject to the reporting person's continued employment through the applicable vesting date. The shares subject to this option vest in approximately equal monthly installments beginning on April 1, 2023 through April 1, 2027. These performance-based stock options, granted on March 16, 2023, vest when the achievement of certain clinical and regulatory development milestones are met. /s/ Michael Vangsted Jensen 2023-11-14